《通货膨胀削减法案》（于 2022年 8 月颁布）对医疗保健和制药行业产生了深远的影响，将药品成本的责任从受益人转移到了计划和制造商身上。The law affects provider reimbursement, changes AMP and ASP calculations, and, perhaps most significantly, allows the federal government to negotiate prices for the first time—all of which present challenges to even the most experienced companies. Join our experts as we break down the Inflation Reduction Act, including how it will be implemented and who is most affected.

Learning objectives:

• Major IRA provisions and timeline for implementation
• Drugs selected for the Drug Price Negotiation Program and implementation by managed care
• Implications for pharma manufacturers